Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells

Biochemical Pharmacology

Volumn 78, Issue 2, 2009, Pages 133-141

  Romani, Antonello A ^a   Desenzani, Silvia ^a   Morganti, Marina M ^a   La Monica, Silvia ^a   Borghetti, Angelo F ^a   Soliani, Paolo ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

Bcl xL; Cell cycle regulators; Cholangiocarcinoma; Cyclins; GGOH; Zoledronic acid

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; GERANYLGERANIOL; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P53; PROTEIN RAP1A; RAP PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DIPLOIDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DIPHOSPHONATES; HUMANS; IMIDAZOLES; S PHASE;

EID: 67349101234     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.004     Document Type: Article

References (58)

1. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 (2005) 1303-1314
2. Blechacz B., and Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (Baltimore, MD) 48 (2008) 308-321
3. Poplin E., Roberts J., Tombs M., Grant S., Rubin E., and Leucovorin. 5-Fluorouracil, and gemcitabine: a phase I study. Invest New Drugs 17 (1999) 57-62
4. Pazdur R., Royce M.E., Rodriguez G.I., Rinaldi D.A., Patt Y.Z., Hoff P.M., et al. Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22 (1999) 78-81
5. Thongprasert S., Napapan S., Charoentum C., and Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16 (2005) 279-281
6. Dive C. Avoidance of apoptosis as a mechanism of drug resistance. J Intern Med Suppl 740 (1997) 139-145
7. Eastman A. Apoptosis: a product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 121 (1993) 160-164
8. Huether A., Hopfner M., Baradari V., Schuppan D., and Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73 (2007) 1308-1317
9. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood 89 (1997) 1845-1853
10. Romani A.A., Soliani P., Desenzani S., Borghetti A.F., and Crafa P. The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer 6 (2006) 255
11. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31 Suppl. 3 (2005) 1-8
12. Aviles A., Nambo M.J., Neri N., Castaneda C., Cleto S., and Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24 (2007) 227-230
13. Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer Suppl. 5 (2005) S54-62
14. Hoesl C.E., and Altwein J.E. Biphosphonates in advanced prostate and renal cell cancer-current status and potential applications. Urol Int 76 (2006) 97-105
15. Melisi D., Caputo R., Damiano V., Bianco R., Veneziani B.M., Bianco A.R., et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12 (2005) 1051-1058
16. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
17. Rodan G.A. Bone mass homeostasis and bisphosphonate action. Bone 20 (1997) 1-4
18. Sonnemann J., Eckervogt V., Truckenbrod B., Boos J., Winkelmann W., and van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 14 (2003) 767-771
19. Mackie P.S., Fisher J.L., Zhou H., and Choong P.F. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Brit J Cancer 84 (2001) 951-958
20. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119 Suppl. 2 (2007) S150-S162
21. Toyras A., Ollikainen J., Taskinen M., and Monkkonen J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci 19 (2003) 223-230
22. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581-589
23. Forsea A.M., Muller C., Riebeling C., Orfanos C.E., and Geilen C.C. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Brit J Cancer 91 (2004) 803-810
24. Iguchi T., Miyakawa Y., Saito K., Nakabayashi C., Nakanishi M., Saya H., et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31 (2007) 285-291
25. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24 (2006) 1145-1152
26. Kuroda J., Kimura S., Segawa H., Sato K., Matsumoto S., Nogawa M., et al. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95 (2004) 186-192
27. Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., and Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71 (2007) 333-343
28. Sewing L., Steinberg F., Schmidt H., and Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13 (2008) 782-789
29. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19 (2002) 607-614
30. Sherr C.J. Cancer cell cycles. Science (New York, NY) 274 (1996) 1672-1677
31. Caca K., Feisthammel J., Klee K., Tannapfel A., Witzigmann H., Wittekind C., et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 97 (2002) 481-488
32. Tannapfel A., Benicke M., Katalinic A., Uhlmann D., Kockerling F., Hauss J., et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47 (2000) 721-727
33. Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Masback A., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92 (2000) 1260-1266
34. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
35. Spruck III C.H., Gonzalez-Zulueta M., Shibata A., Simoneau A.R., Lin M.F., Gonzales F., et al. p16 gene in uncultured tumours. Nature 370 (1994) 183-184
36. Pagano M., Pepperkok R., Verde F., Ansorge W., and Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11 (1992) 961-971
37. Dunphy W.G., Brizuela L., Beach D., and Newport J. The Xenopus cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 54 (1988) 423-431
38. Okaro A.C., Deery A.R., Hutchins R.R., and Davidson B.R. The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 54 (2001) 927-932
39. Okaro A.C., Fennell D.A., Corbo M., Davidson B.R., and Cotter F.E. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Gut 51 (2002) 556-561
40. Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., and Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (Georgetown, TX) 5 (2006) 2592-2601
41. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 33-42
42. Malhi H., and Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45 (2006) 856-867
43. Reddig P.J., and Juliano R.L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24 (2005) 425-439
44. Bucher N., and Britten C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Brit J Cancer 98 (2008) 523-528
45. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15 (2003) 158-163
46. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170 (2003) 246-252
47. Croucher P., Jagdev S., and Coleman R. The anti-tumor potential of zoledronic acid. Breast 12 Suppl. 2 (2003) S30-S36
48. Li X., Marani M., Mannucci R., Kinsey B., Andriani F., Nicoletti I., et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 61 (2001) 1699-1706
49. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 (2001) 2602-2608
50. Li Y.Y., Chang J.W., Chou W.C., Liaw C.C., Wang H.M., Huang J.S., et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59 (2008) 180-191
51. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15 (2000) 2211-2221
52. Harnois D.M., Que F.G., Celli A., LaRusso N.F., and Gores G.J. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology (Baltimore, MD) 26 (1997) 884-890
53. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., and Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12 (1998) 220-229
54. Blanco-Colio L.M., Justo P., Daehn I., Lorz C., Ortiz A., and Egido J. Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. Kidney Int 64 (2003) 181-191
55. Hayward R.L., Macpherson J.S., Cummings J., Monia B.P., Smyth J.F., and Jodrell D.I. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 9 (2003) 2856-2865
56. Richards E.H., Hickey E., Weber L., and Master J.R. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56 (1996) 2446-2451
57. Mori-Iwamoto S., Kuramitsu Y., Ryozawa S., Mikuria K., Fujimoto M., Maehara S., et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31 (2007) 1345-1350
58. Romani A.A., Crafa P., Desenzani S., Graiani G., Lagrasta C., Sianesi M., et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. BMC Cancer 7 (2007) 232